Edinburgh is home to a buzzing AI startup and spinout scene - and we are at the heart of it. We run several programmes to empower AI entrepreneurs with the skills, contacts and resources to make their ideas a reality, benefiting businesses, consumers and the economy. We have a portfolio of opportunities available for AI and digital external founders and companies, as well as students and researchers at the University of Edinburgh. The suite of resources includes a business development programme for AI driven scaleups, and a programme to validate the commercial potential of digital ideas and innovations. We offer entrepreneurs skills and insights for their investment journey and support access to finance and investment.Activity is led by the Bayes Centre, the University of Edinburgh’s Innovation Hub for Data Science and Artificial Intelligence, in partnership with Edinburgh Innovations.Accelerating Entrepreneurship AI AcceleratorThe AI Accelerator programme nurtures AI driven scaleups, supporting them to bring about transformative change in areas of global challenge. With AI technology efficiencies, companies on this cohort are creating new propositions with the potential to disrupt the market.Since 2019, 106 companies have been supported and more than £130 million funding has been raised. Applications to be part of the next cohort open in April 2025. AI AcceleratorCase study: BioLibertyVenture Builder IncubatorThe Venture Builder Incubator programme specialises in helping PhD students bridge the gap between academia and entrepreneurship. By guiding participants to develop a robust commercialisation and funding strategy, the programme supports the entrepreneurial cohort to validate the commercial potential of digital and science-based ideas and innovations. The programme has supported 164 founders and companies since 2021, who have gone on to raise £58 million in grants and investments.Venture Builder IncubatorCase study: Bennu.ai Explore our spinouts and startupsWith a sharp focus on future health and care, data and digital, and sustainability our spin-out companies are pushing boundaries in research, driving innovation and delivering impact for the benefit of our society and our planet. Trogenix University of Edinburgh spinout Trogenix is developing a gene therapy platform that targets aggressive cancers, including glioblastoma, using synthetic super-enhancers to selectively destroy tumour cells whilst leaving healthy tissue unharmed. In preclinical trials, the approach achieved complete tumour elimination in 83% of treated mice, with no off-target toxicity. Backed by £70m in Series A funding, the company began its first human clinical trial in May 2026. Aveni Award-winning fintech company Aveni is spearheading a revolution in financial services productivity by fusing advanced AI with human ingenuity. The University startup company’s solutions are accelerating financial services workflows by providing automated admin support and quality assurance, analysing customer interactions and providing actionable insights. Qinara Qinara is a hybrid quantum-classical computing company focused on enhancing AI systems. By integrating cutting-edge quantum techniques into real-world systems, Qinara is creating solutions that deliver high-performance intelligence in a way that’s affordable, reliable, and ready for deployment across sectors such as cybersecurity, biomedicine and finance. Prothea Technologies Deep-tech spinout Prothea Technologies Ltd is developing tech to ‘see and treat’ diseased lung tissue in one hospital visit. Lung cancer is the third most common cancer in the UK but the team behind Prothea say their technology could alleviate hospital pressure and pave the way for diagnosis and treatment to be carried out in a single hospital visit. Concinnity Award-winning spinout company Concinnity Genetics is transforming the safety of gene therapies by designing novel control mechanisms using its cutting-edge AI platform and synthetic biology expertise. Concinnity Genetics has developed novel RNA-based systems that enable the precise control of gene therapies even after dosing, conveying the ability to respond to and reduce their own side effects as well as improve the efficacy of these innovative treatments. Neuranics Neuranics is a joint spinout from the Universities of Edinburgh and Glasgow, developing high-precision bio-magnetic sensors using tunnel magnetoresistance (TMR) quantum technology. By detecting tiny magnetic fields generated by muscle activity, the sensors improve human-machine interfaces across wearables, consumer electronics, prosthetics, and extended reality. The company raised $8m in 2025, backed by Old College Capital and other investors, to accelerate global commercialisation. Omecu University of Edinburgh spinout company Omecu is developing a high-performance genomics and health data analysis platform. The Omecu team has developed a computation engine and web platform that is capable of powerful and highly sophisticated analyses, giving researchers the freedom to interactively query multiple federated genomic datasets and get the answers they need in seconds. Related linksBayes CentreEdinburgh InnovationsImage credit: Entrepreneur - Maverick Photography. Aveni: Thananit - stock.adobe.com; Concinnity: Calima - stock.adobe.com; Neuranics: supplied by the company; Omecu: NicoEINino - stock.adobe.com; Prothea: abvbakarrr - stock.adobe.com; Trogenix: Chinnapong - stock.adobe.com. This article was published on Tuesday 11 March 2025
